Selexa-400 Warnings

Statement according to Announcement of Ministry of Public Health: Contraindicated in patients who are sensitive to this drug, pregnancy and lactating women.
Contraindicated in patients who have undergone immediate post-operative from CABG surgery.
Contraindicated in patients with cardiovascular or cerebrovascular diseases.
Contraindicated in patients with history of sulfonamides hypersensitivity due to the risk of severe skin adverse reactions.
Contraindicated in patients with myocardial infarction or congestive heart failure class NYHA II-IV.
Contraindicated in patients with history of coronary artery disease or paresis/paralysis from stroke.
Use with caution in patients with risk factors for cardiovascular disease such as hypertension, hyperlipidemia, diabetes mellitus, smoking, elderly etc.
Use with caution in patients with hepatic and renal impairment.
Cardiovascular: NSAIDs are associated with an increased risk of serious adverse cardiovascular thrombotic events, including Ml and stroke. Risk of cardiovascular events may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profile prior to prescribing. New onset or exacerbation of hypertension may occur; may contribute to cardiovascular event. Celecoxib should be used with caution in patients with hypertension. Celecoxib may cause sodium and fluid retention. Celecoxib should be used with caution in patients with edema, cerebrovascular disease or ischemic heart disease.
GI: NSAIDs may increase risk of serious gastrointestinal ulceration, bleeding and perforation. Use caution with history of GI disease (bleeding or ulcer), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking.
Hepatic: Severe reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure have been reported rarely in patients receiving NSAIDs. Celecoxib should be discontinued if clinical sign and symptoms consistent with liver disease develop.
Other: Use of corticosteroids during NSAIDs therapy may increase the risk of GI ulceration, the drugs should be used concomitantly with caution.
Anaphylactoid reactions may occur in patients receiving celecoxib, even without prior exposure.
Serious skin reactions (e.g. exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis) can occur in patients receiving celecoxib. These serious skin reactions can occur without warning and in patients without history of sulfonamide sensitivity reactions. Celecoxib should be discontinued at the first appearance of rash or any other sign of hypersensitivity.
Patient with asthma may have aspirin-sensitivity asthma; celecoxib should be used with caution in patient with asthma.